Drug Combination Details
| General Information of the Combination (ID: C95252) | |||||
|---|---|---|---|---|---|
| Name | Curcumin NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Prostate cancer
[ICD-11: 2C82]
|
Investigative | [1] | ||
|
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [2] | |||
|
Adrenocortical carcinoma
[ICD-11: 2D11]
|
Investigative | [3] | |||
|
Breast cancer
[ICD-11: 2C60]
|
Investigative | [4] | |||
|
Stomach cancer
[ICD-11: 2B72]
|
Investigative | [5] | |||
| Click to Show/Hide the Whole Disease Information of This Combination | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [5] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | AGS | CVCL_0139 | Gastric adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Dox-Cur combination therapy exerts more profound apoptotic and anticancer effects on the AGS cell line than curcumin or doxorubicin monotherapy. | |||||
| Experiment 2 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Activity | p105 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Induction | Cell cycle arrest in G1 phase | ||||
| In-vitro Model | PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | ||
| DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Curcumin enhances cytotoxicity of doxorubicin in prostate cancer cells by inducing p21(WAF1/CIP1) and C/EBPbeta expressions and suppressing NF-kappaB activation. | |||||
| Experiment 3 Reporting the Effect of This Combination | [2] | |||||
| In-vitro Model | M5076 | CVCL_3997 | Mouse ovarian histiocytic sarcoma | Mus musculus | ||
| In-vivo Model | M5076 ovarian sarcoma cells (1.0*106 cells/animal) were transplanted i.p. into C57BL/6 mice. | |||||
| Experimental
Result(s) |
While DOX alone did not decrease tumor weight, the combination of DOX and curcumin significantly reduced tumor weight. The combined curcumin enhanced apoptosis by DOX, decreased cell viability and suppressed activation of caspase-3, -8, and -9 compared to DOX alone. | |||||
| β. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [4] | |||||
| Molecule(s)
Regulation |
Down-regulation | Activity | ABCB4 | Molecule Info |
Pathway MAP
|
|
| Biological
Regulation |
Down-regulation | ABCB4-mediated doxorubicin transport | ||||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | |||
| MDCK-II | CVCL_0424 | Healthy | Canis lupus familiaris | |||
| Experimental
Result(s) |
Curcumin reversed doxorubicin resistance in human breast cancer MCF 7/DOX and MDA MB231/DOX cells by inhibiting the ATPase activity of ABCB4. | |||||
